AZ and Amgen tried and failed to develop tezepelumab as a therapy for atopic dermatitis, chalking up one failed phase 3 trial in 2017, but have continued to develop the drug for other indications ...

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not be ...

Patients with unilateral chronic rhinosinusitis with nasal polyps (CRSwNP) tend to have less severe disease than those with bilateral nasal polyps and generally have better outcomes than those with ...

The role of the nasal microbiome in chronic rhinosinusitis (CRS) is generating increasing interest. A review article in the journal Pathogens details recent findings on the correlation between ...